Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta
研究概览
详细说明
Recombinant IFN alfa possesses anti-viral and immunomodulatory effects and has been shown to be effective in chronic hepatitis B [Davis et al. 1989; Bisceclie et al, 1989]. Interferon alfa is also one of the approved treatments for chronic hepatitis B. Administration of IFN alfa-2b to adults leads to disappearance of HBV DNA with or without HBeAg seroconversion in 30-50% of patients, which is two to three times above the rate of yearly spontaneous HBeAg seroconversion (10-15%). Normalization of serum ALT occurs in most cases. Loss of HBsAg is observed in 10-15% of Caucasian patients during the prolonged post-treatment follow-up period. Recently, studies suggested that a higher proportion of patients receiving pegylated IFN could achieve HBeAg seroconversion and control of HBV replication [Marcellin et al, 2004; Lau et al, 2004; Jensen et al, 2004].
RBV is another antiviral nucleotide analogue with few adverse effects [Sidwell et al, 1972; Patterson et al, 1990]. RBV alone can modestly inhibit HDV or HBV replication [Choi et al, 1989]. The beneficial effect of combined IFN plus RBV in the treatment of chronic hepatitis B has also been shown in previous studies [Cotonat et al, 2000]. Why RBV can greatly enhance the treatment efficacy is not clear. It had been shown that ribavirin could inhibit interleukin-4, an inhibitor of cytotoxic T lymphocyte activity, and preserves the interleukin-2 and gamma IFN activities. Other studies revealed that the enhanced efficacy was associated with HBV- or other virus-specific type 1 cytokine-mediated T helper cell responses [Cramp et al, 2000; Tam et al, 1999; Hultgren et al, 1998; Fang et al, 2002; Fang et al, 2000; Rico et al, 2001]. Thus, the combination therapy may augment virus-specific cytotoxic T lymphocytes and non-specific immune response, and effectively shift the immune responses to the more potent antiviral type 1 T-helper profile [Hultgren et al, 1998].
HDV, like HCV, is a RNA virus. Indeed, RBV had also been shown to be active against HDV replication in cell cultures [Choi et al, 1989]. The investigators therefore hypothesize that pegylated IFN alfa-2b in combination with RBV can yield an efficacy in chronic hepatitis D patients who are dually infected by HBV. The purpose of this protocol is to test this hypothesis. A previous study found that high-dose IFN may improve the efficacy for chronic hepatitis D patients. Another pilot study using IFN alfa plus RBV also demonstrated that the seroclearance of HCV RNA was not affected by HBV coinfection [Liu et al, 2003]. The investigators thus use pegylated IFN alfa-2b in combination with RBV for the treatment of patients with dual chronic HDV and HBV infection.
The treatment choice for chronic hepatitis D was not clarified till now. In this proposal, the dosage and duration for the combination regimen are decided mainly by the experience from the treatment of chronic hepatitis B and chronic hepatitis C.
The investigators recent study using ribavirin and interferon (IFN) combination therapy for dual chronic hepatitis B and C suggested that combining ribavirin 1,200 mg daily for 6 months, together with 6 million units (MU) IFN-alpha 2a thrice weekly for 12 weeks and then 3 MU for another 12 weeks was effective for the clearance of HCV RNA [Liu et al, 2003]. Twenty-four patients with chronic hepatitis seropositive for both hepatitis B surface antigen and antibody to HCV received ribavirin 1,200 mg daily for 6 months, together with 6 million units (MU) IFN-alpha 2a thrice weekly for 12 weeks and then 3 MU for another 12 weeks. The serum HCV clearance rate was 43% 24 weeks posttreatment. The serum ALT normalization rate was 43% 24 weeks posttreatment. In hepatitis B and C dually infected patients, combination IFN with ribavirin can achieve a sustained HCV clearance rate comparable with hepatitis C alone. Furthermore, a previous study revealed that a 12-week RBV therapy was not effective for patients with chronic hepatitis B [Kakumu et al, 1993]. Therefore, a 24-week course of combination therapy pegylated IFN+RBV will be used.
Increased RBV dosage has been considered a contributory factor to the better efficacy in treating refractory genotype HCV. For example, recent studies suggested that using RBV 800 mg daily is adequate to treat HCV genotype non-1 while the standard dosage of RBV is required to treat HCV genotype 1 [NIH 2002]. The investigators thus propose to use RBV 1000-1200 mg daily according to the body weight of the patient.
研究类型
注册
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Pei-Jer Chen, M.D., Ph.D.
- 电话号码:7072 886-2-23123456
- 邮箱:peijer@ha.mc.ntu.edu.tw
学习地点
-
-
-
Taipei、台湾、100
- 招聘中
- National Taiwan University Hospital
-
Taipei、台湾、100
- 尚未招聘
- National Taiwan University
-
首席研究员:
- Pei-Jer Chen, M.D., Ph.D.
-
接触:
- Pei-Jer Chen, M.D.; Ph.D.
- 电话号码:7072 886-2-23123456
- 邮箱:peijer@ha.mc.ntu.edu.tw
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Be positive for both anti-HDV and HBsAg for more than 6 months
- Present with elevated serum ALT levels at least 1.5 times the upper limit of normal, documented on two occasions (at least one month apart), within six months prior to enrollment
- Be HDV RNA positive by PCR (sensitivity: 103 copies/mL) [Yamashiro et al, 2004]
- Be HBV DNA positive by PCR
- Present with liver biopsy findings compatible with the diagnosis of chronic liver disease (the liver biopsy needs to be taken within 52 weeks prior to enrollment)
- Have adequate liver reserve (defined as equal to or better than Child-Pugh Class A)
- Present with WBC ≥3000/mm3, ANC ≥1500/mm3, and platelet ≥80,000/mm3
- Be able to and likely to attend regularly for treatment and follow-up
- Give their written informed consent
- Be negative for urine pregnancy test (for females of childbearing potential), documented once within the screening period and again within 24 hours prior to the first dose of study drug
- All male patients with female partners of childbearing age should use a barrier method of contraception
- All female patients of childbearing potential must use two reliable forms of effective contraception
Exclusion Criteria:
- Drug addicts or have any history or histological evidence of alcohol abuse, or currently receive prescriptions that may cause hepatotoxicity
- Have decompensated cirrhosis as coded by Child-Pugh classification (i.e. history of ascites, history of bleeding from esophageal varices, severe portal hypertension, serum albumin <30 g/l, serum bilirubin >30 mg/l)
- Present with WBC <3000/mm3, ANC <1500/mm3, or platelets <90,000/mm3
- Present with hemoglobin <12.0 gm/dl for female and <13.0 gm/dl for male
- Have been treated with immunosuppressive therapy within the past six months (e.g. steroids, azathioprine, cyclophosphamide)
- Have renal insufficiency (serum creatinine >150 μmol/l)
- Have clotting abnormalities which preclude a liver biopsy
- Have evidence of any serious neurological dysfunction
- Have obesity or diabetes mellitus-induced liver disease
- Have serological evidence of autoimmune chronic liver disease (e.g. antinuclear antibody titers >1:320, and/or smooth muscle antibody titers>1:160)
- Hemophiliacs
- Have evidence of inheritable disorders such as haemochromatosis, alpha-1-antitrypsin deficiency or Wilson's disease
- Have been exposed to hepatotoxic substances which might be the cause of hepatitis
- Pregnant, lactating or not practicing an adequate form of birth control, such as oral contraceptives or intrauterine devices
- Seropositive for anti-HIV or anti-HCV
- Have serious psychological or psychiatric problems disrupting daily activities
- Have AFP (alpha-fetoprotein) greater than 20 ng/ml; in case of elevated AFP, abdomen ultrasonography is required to exclude the possibility of HCC
- Have serious heart diseases (coronary heart disease, etc)
- Have a history of asthma or drug allergy which may lead to hypersensitivity to ribavirin
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
结果测量 |
---|
the efficacy of 24-week pegylated IFN alfa-2b plus RBV for SVR of HDV in patients with dual chronic hepatitis D and B
|
次要结果测量
结果测量 |
---|
the efficacy of pegylated IFN alfa-2b plus RBV in patients with dual chronic hepatitis D and B on: The biochemical response rate
|
The degree of histologic change
|
合作者和调查者
调查人员
- 首席研究员:Pei-Jer Chen, M.D., Ph.D.、National Taiwan University Hospital
研究记录日期
研究主要日期
学习开始
研究完成
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
慢性乙型肝炎的临床试验
-
Lapo Alinari招聘中伴有 MYC、BCL2 和 BCL6 重排的复发性高级别 B 细胞淋巴瘤 | 具有 MYC、BCL2 和 BCL6 重排的难治性高级 B 细胞淋巴瘤 | 伴有 MYC 和 BCL2 或 BCL6 重排的复发性高级别 B 细胞淋巴瘤 | 具有 MYC 和 BCL2 或 BCL6 重排的难治性高级 B 细胞淋巴瘤 | 复发性弥漫性大 B 细胞淋巴瘤活化 B 细胞型 | 难治性弥漫性大 B 细胞淋巴瘤活化 B 细胞型 | 将惰性 B 细胞非霍奇金淋巴瘤转化为弥漫性大 B 细胞淋巴瘤 | 复发性弥漫性大 B 细胞淋巴瘤生发中心 B 细胞型 | 难治性弥漫性大 B 细胞淋巴瘤生发中心 B 细胞型美国
-
Northwestern UniversityNational Cancer Institute (NCI)主动,不招人弥漫性大 B 细胞淋巴瘤 | 弥漫性大 B 细胞淋巴瘤,未另行说明 | 高级 B 细胞淋巴瘤,未另行说明 | 富含 T 细胞/组织细胞的大 B 细胞淋巴瘤 | 具有 MYC 和 BCL2 和/或 BCL6 重排的高级别 B 细胞淋巴瘤 | 弥漫性大 B 细胞淋巴瘤活化 B 细胞型 | 弥漫性大 B 细胞淋巴瘤生发中心 B 细胞型美国
-
Ohio State University Comprehensive Cancer Center招聘中弥漫性大 B 细胞淋巴瘤 | 高级别 B 细胞淋巴瘤 | 弥漫性大 B 细胞淋巴瘤,未另行说明 | 弥漫性大 B 细胞淋巴瘤生发中心 B 细胞型美国
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Amgen主动,不招人复发性弥漫性大 B 细胞淋巴瘤 | 难治性弥漫性大 B 细胞淋巴瘤 | CD20阳性 | I 期弥漫性大 B 细胞淋巴瘤 | II 期弥漫性大 B 细胞淋巴瘤 | III 期弥漫性大 B 细胞淋巴瘤 | IV 期弥漫性大 B 细胞淋巴瘤美国
-
Curocell Inc.招聘中高级别 B 细胞淋巴瘤 | 弥漫性大 B 细胞淋巴瘤 (DLBCL) | 原发性纵隔大 B 细胞淋巴瘤 (PMBCL) | 转化的滤泡性淋巴瘤 (TFL) | 难治性大 B 细胞淋巴瘤 | 复发性大 B 细胞淋巴瘤大韩民国
-
National Cancer Institute (NCI)招聘中高级别 B 细胞淋巴瘤 | 弥漫性大 B 细胞淋巴瘤,未另行说明 | 将惰性 B 细胞非霍奇金淋巴瘤转化为弥漫性大 B 细胞淋巴瘤美国
-
Nathan DenlingerBristol-Myers Squibb招聘中B 细胞非霍奇金淋巴瘤复发 | 弥漫性大 B 细胞淋巴瘤复发 | 滤泡性淋巴瘤-复发性 | 高级别 B 细胞淋巴瘤-复发 | 原发性纵隔大 B 细胞淋巴瘤复发 | 惰性 B 细胞非霍奇金淋巴瘤转化为弥漫性大 B 细胞淋巴瘤复发 | 难治性 B 细胞非霍奇金淋巴瘤 | 难治性弥漫性大 B 细胞淋巴瘤 | 滤泡性淋巴瘤难治性 | 高级别 B 细胞淋巴瘤难治性 | 原发性纵隔大 B 细胞淋巴瘤难治性 | 将惰性 B 细胞非霍奇金淋巴瘤转化为难治性弥漫性大 B 细胞淋巴瘤美国
-
National Cancer Institute (NCI)主动,不招人
-
Northwestern UniversityNational Cancer Institute (NCI)招聘中复发性原发性纵隔(胸腺)大 B 细胞淋巴瘤 | 难治性原发性纵隔(胸腺)大 B 细胞淋巴瘤 | 伴有 MYC、BCL2 和 BCL6 重排的复发性高级别 B 细胞淋巴瘤 | 具有 MYC、BCL2 和 BCL6 重排的难治性高级 B 细胞淋巴瘤 | 复发性弥漫性大 B 细胞淋巴瘤,未另行说明 | 难治性弥漫性大 B 细胞淋巴瘤,未另行说明 | 复发性侵袭性 B 细胞非霍奇金淋巴瘤 | 难治性侵袭性 B 细胞非霍奇金淋巴瘤 | 复发性转化 B 细胞非霍奇金淋巴瘤 | 难治性转化 B 细胞非霍奇金淋巴瘤 | EBV 阳性弥漫性大 B 细胞淋巴瘤,未另行说明 | 高级 B 细胞淋巴瘤,未另行说明 | 与慢性炎症相关的弥漫性大 B 细胞淋巴瘤 | 伴 IRF4... 及其他条件美国
-
Patrick C. Johnson, MDAstraZeneca招聘中难治性 B 细胞非霍奇金淋巴瘤 | 弥漫性大 B 细胞淋巴瘤 (DLBCL) | 3b 级滤泡性淋巴瘤 | 难治性侵袭性 B 细胞淋巴瘤 | 侵袭性 B 细胞 NHL | 从头或转化的惰性 B 细胞淋巴瘤 | DLBCL,Nos 遗传亚型 | 富含 T 细胞/组织细胞的大 B 细胞淋巴瘤 | EBV 阳性 DLBCL,编号 | 原发性纵隔 [胸腺] 大 B 细胞淋巴瘤 (PMBCL) | 高级 B 细胞淋巴瘤,编号 | C-MYC/BCL6 双重打击高级别 B 细胞淋巴瘤 | C-MYC/BCL2 双重打击高级别 B 细胞淋巴瘤美国
pegylated IFN alfa-2b plus ribavirin的临床试验
-
ANRS, Emerging Infectious DiseasesFlamel Technologies未知
-
European Organisation for Research and Treatment...NCIC Clinical Trials Group未知
-
Merck Sharp & Dohme LLC完全的艾滋病毒感染 | 丙型肝炎 | 慢性丙型肝炎
-
Merck Sharp & Dohme LLC终止
-
Merck Sharp & Dohme LLC终止
-
Hoffmann-La Roche完全的丙型肝炎,慢性比利时, 法国, 德国, 瑞典, 瑞士, 火鸡, 希腊, 爱尔兰, 台湾, 爱沙尼亚, 匈牙利, 意大利, 罗马尼亚, 英国, 塞尔维亚, 摩洛哥, 葡萄牙, 沙特阿拉伯, 埃及, 巴基斯坦, 黎巴嫩, 马其顿,前南斯拉夫共和国, 阿曼, 卡塔尔, 阿拉伯叙利亚共和国, 阿拉伯联合酋长国, 科威特
-
National Cancer Institute (NCI)终止
-
Tibotec BVBA完全的慢性丙型肝炎法国, 西班牙, 比利时, 德国, 奥地利, 荷兰
-
National Cancer Institute (NCI)完全的